AbbVie Faces 1st Antitrust Suit Over Humira 'Patent Thicket'

Law360 (March 18, 2019, 11:11 PM EDT) -- AbbVie Inc.'s colossal "patent thicket" for its $20-billion-per-year immunosuppressant Humira has empowered it to block less-expensive biosimilars in violation of numerous antitrust laws, according to a first-of-its-kind suit launched Monday.

A grocery union is accusing AbbVie of blocking biosimilars of its biologic Humira. (AP) In a proposed class action filed in Illinois federal court, the largest grocery union in New York accuses Illinois-based AbbVie of misconduct in connection with a war chest of more than 100 patents that has helped the company keep biosimilar versions of Humira off the U.S. market until 2023.

"It simply is not feasible for biosimilar manufacturers to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS